» Articles » PMID: 31576172

Long Non-coding RNA TUG1-mediated Down-regulation of KLF4 Contributes to Metastasis and the Epithelial-to-mesenchymal Transition of Colorectal Cancer by MiR-153-1

Overview
Publisher Dove Medical Press
Specialty Oncology
Date 2019 Oct 3
PMID 31576172
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Taurine up-regulated 1 (TUG1) was reported to be over-expressed and involved in various human malignancies. However, its expression status and mechanistic importance in colorectal cancer (CRC) were yet to be defined.

Methods: Relative expressions of TUG1, miR-153-1 and Kruppel-like factor 4 (KLF4) were analyzed by real-time PCR. The potential influences of TUG1-proficiency and miR-153-1-deficiency on cell proliferation, migration and viability were determined by colony formation, wound healing and CCK-8 assays, respectively. Cell invasion was evaluated by transwell chamber assay. The regulatory effect of KLF4 on miR-153-1 was interrogated by luciferase reporter assay. Direct association between KLF4 and miR-153-1 promoter was measured by chromatin immunoprecipitation (ChIP) assay. Subcellular localization of TUG1 was determined by fractionization PCR. Enrichment of EZH2 on KLF4 promoter was analyzed by ChIP-PCR. The pro-tumoral activity of TUG1 was determined using xenograft tumor model.

Results: We demonstrated the over-expression of TUG1 and down-regulation of miR-153-1 in CRC. Knockdown of TUG1 or ectopic over-expression of miR-153-1 in SW480 significantly suppressed cell proliferation, migration and viability. TUG1 negatively modulated miR-153-1 expression, and simultaneous expression of TUG1 completely abolished the anti-tumor effect of miR-153-1. We further identified KLF4 as a transcription factor of miR-153-1, which was negatively regulated by TUG1 along with EZH2.

Conclusion: Our study unravels the critical involvement of TUG1/KLF4/miR-153-1 axis in CRC.

Citing Articles

RNF112, whose transcription is regulated by KLF4, inhibits colorectal cancer growth via promoting ubiquitin-dependent degradation of NAA40.

Li C, Guan W, Geng D, Feng Y Cell Biol Toxicol. 2025; 41(1):22.

PMID: 39757327 PMC: 11700914. DOI: 10.1007/s10565-024-09977-z.


Competitive endogenous RNA networks: Decoding the role of long non-coding RNAs and circular RNAs in colorectal cancer chemoresistance.

Khalafizadeh A, Hashemizadegan S, Shokri F, Bakhshinejad B, Jabbari K, Motavaf M J Cell Mol Med. 2024; 28(7):e18197.

PMID: 38506091 PMC: 10951891. DOI: 10.1111/jcmm.18197.


Long noncoding RNA TUG1 regulates smooth muscle cell differentiation via KLF4-myocardin axis.

Bharadhwaj R, Kumarswamy R Am J Physiol Cell Physiol. 2023; 325(4):C940-C950.

PMID: 37642238 PMC: 10635660. DOI: 10.1152/ajpcell.00275.2023.


Krüppel-like Factors 4 and 5 in Colorectal Tumorigenesis.

Lee E, Cheung J, Bialkowska A Cancers (Basel). 2023; 15(9).

PMID: 37173904 PMC: 10177156. DOI: 10.3390/cancers15092430.


Non-coding RNAs and Exosomal Non-coding RNAs in Traumatic Brain Injury: the Small Player with Big Actions.

Mohamadzadeh O, Hajinouri M, Moammer F, Tamehri Zadeh S, Omid Shafiei G, Jafari A Mol Neurobiol. 2023; 60(7):4064-4083.

PMID: 37020123 DOI: 10.1007/s12035-023-03321-y.


References
1.
Brody H . Colorectal cancer. Nature. 2015; 521(7551):S1. DOI: 10.1038/521S1a. View

2.
Cui Y, Zhao J, Yi L, Jiang Y . microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells. PLoS One. 2016; 11(6):e0156915. PMC: 4905671. DOI: 10.1371/journal.pone.0156915. View

3.
Chen R, Kong P, Zhang F, Shu Y, Nie X, Dong L . EZH2-mediated α-actin methylation needs lncRNA TUG1, and promotes the cortex cytoskeleton formation in VSMCs. Gene. 2017; 616:52-57. DOI: 10.1016/j.gene.2017.03.028. View

4.
Zhai F, Cao C, Zhang L, Zhang J . miR-543 promotes colorectal cancer proliferation and metastasis by targeting . Oncotarget. 2017; 8(35):59246-59256. PMC: 5601729. DOI: 10.18632/oncotarget.19495. View

5.
Cao J, Han X, Qi X, Jin X, Li X . TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p. Int J Oncol. 2017; 51(4):1115-1123. PMC: 5592872. DOI: 10.3892/ijo.2017.4110. View